Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PMS1 homolog 1 (abbreviated as PMS1) is an enzyme that is part of the DNA mismatch repair (MMR) system, classified within the mutL/hexB protein family[1][2][4]. PMS1 forms heterodimers with MLH1, another key mismatch repair protein, to correct base mispairing and insertion/deletion loops during DNA replication[2][4][7]. Mutations in PMS1 can compromise genomic stability and are associated with hereditary nonpolyposis colorectal cancer type 3 (HNPCC3), also called Lynch syndrome[2][4]. While PMS1 is critical for maintaining DNA integrity, it is not recognized as a current therapeutic target for drug development, and there are no approved drugs known to directly interact with or modulate its activity[2][5][7]. Its chief clinical importance lies in its use as a biomarker in genetic testing for Lynch syndrome and related cancers[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PMS1 homolog 1, mismatch repair system component (PMS1).